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ABSTRACT 
Background: Altered cellular metabolism is a hallmark of cancer and some are reliant on Glutamine for 
sustained proliferation and survival. We hypothesise that the Glutamine-Proline regulatory axis has a key role in 
Breast cancer (BC) in the highly proliferative classes.  
Methods: Glutaminase (GLS), pyrroline-5-carboxylate synthetase (ALDH18A1) and pyrroline-5-carboxylate 
reductase 1 (PYCR1) were assessed at DNA/mRNA/protein levels in large well-characterised cohorts.  
Results: Gain of PYCR1 copy number and high PYCR1 mRNA was associated with luminal B tumours. High 
ALDH18A1 and high GLS protein expression was observed in the ER+/HER2- high proliferation class (Luminal 
B) compared with ER+/HER2- low proliferation class (Luminal A) (p=0.030 and p=0.022 respectively), however 
this was not observed with mRNA. Cluster analysis of the Glutamine-Proline regulatory axis genes revealed 
significant associations with molecular subtypes of breast cancer and patient outcome independent of standard 
clinicopathological parameters (p=0.012).  High protein expression of the Glutamine-Proline enzymes were all 
associated with high MYC protein in Luminal B tumours only (p<0.001).  
Conclusion: We provide comprehensive clinical data indicating that the Glutamine-Proline regulatory axis plays 
an important role in the aggressive subclass of luminal BC and is therefore a potential therapeutic target. 
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1. Introduction 
Deregulation of metabolic pathways has been readily accepted as part of the revised hallmarks of cancer where 
cancer cells are able to regulate their metabolism to provide energy and cellular building blocks required for 
growth (Hanahan & Weinberg, 2011). Many cancer cells are highly reliant on amino acids for their growth where 
endogenous synthesis may not provide the rapidly proliferating cells with sufficient nutrients for nuclear 
biosynthesis.  There is also increasing evidence that oncogenes and/or tumour-suppressor genes can reprogram 
tumour cell metabolism including the direct regulation of the glutamine (Gln)-proline (Pro) regulatory axis by 
MYC and p53 (Cao et al, 2014; Kardos et al, 2015; Wise & Thompson, 2010) . This axis is the most important 
metabolic pathway in tumours after glucose primarily as Gln is used to replenish the tricarboxylic-acid (TCA) 
cycle and supplies carbon and nitrogen for synthesis of nucleotides, amino acids and glutathione. Indeed, some 
solid tumours have glutamine dependent cell growth or “glutamine addiction” (Wise & Thompson, 2010). 
Gln is a non-essential amino acid synthesised by glutamine synthetase (GS) from glutamate and ammonia. Its 
utilisation, via reductive carboxylation, is necessary for sustained proliferation/survival and is linked with 
resistance to certain drugs (Soria et al, 2010). A further role for Gln in cancer cell protein translation stems from 
observations that a master regulator of protein translation, rapamycin complex 1 (mTORC1), which regulates cell 
growth and protein translation, is also responsive to Gln levels (McShane et al, 2005; Phang et al, 2015).  In 
breast cancer (BC), high-grade highly proliferative tumours such as the triple negative (TN), have higher levels of 
glutamate and glutaminase (GLS) together with low levels of Gln than low grade tumours and normal breast 
epithelium (Gao et al, 2009; Kuo et al, 2016; Liu et al, 2012; Richardson et al, 2008; Wise et al, 2008). Metabolic 
profiles of BC show glutaminolysis metabolism as a key pathway discriminating between TN and oestrogen 
receptor (ER)+ tumours (Cao et al, 2014). The CB-839 small-molecule selective inhibitor of GLS which has anti-
tumour activity in TNBC cell lines is currently being tested in phase I clinical trials (NCT02071862) (Gao et al, 
2009).  
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Gln is converted to glutamate by GLS before entering the TCA cycle as a precursor to α-ketoglutarate, an 
important energy source which is synthesised by glutamate dehydrogenase. However, glutamate can also be 
converted into proline via the enzymes pyrroline-5-carboxylate synthetase (ALDH18A1) and pyrroline-5-
carboxylate reductase 1 (PYCR1) which subsequently produces NADP used to fuel the breakdown of glucose by 
glycolysis (Kardos et al, 2015) (Figure 1). ALDH18A1 is responsible for reducing glutamate to Gln 
semialdehyde; a crucial step in the de novo biosynthesis of proline (Database, 2016).  
With renewed interest in oncometabolism, metabolic enzymes are increasingly targeted to improve therapeutic 
efficacy and reduce resistance. We therefore hypothesised that the Pro-Gln axis is a key metabolic pathway 
regulated by MYC in BC particularly as we have recently showed proline dehydrogenase (PRODH) to be down 
regulated (Kardos et al, 2015). This pathway could be used as a potential therapeutic target particularly as the 
pleotropic MYC has so far proved ineffective.  
The aim of this study was to conduct a comprehensive genomic, transcriptomic and proteomic analysis of the 
Gln-Pro regulatory axis in the molecular subtypes of breast cancer and their associations with MYC. More 
specifically, we aim to determine GLS, ALDH18A1 and PYCR1 gene copy number and gene expression; together 
with its protein expression, in large well-characterised annotated cohorts of BC to determine their biological, 
clinicopathological and prognostic value in the different molecular classes with particular interest in the highly 
proliferative aggressive subgroups as potential therapeutic targets.  
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2. METHODS  
2.1 Gln-Pro enzymes copy number and gene expression 
PYCR1, ALDH18A1, GLS and MYC copy number and gene expression were evaluated in a cohort of 1,980 breast 
cancer samples using the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) cohort 
(Curtis et al, 2012). METABRIC provides data on genomic and transcriptomic profiling of breast cancer using the 
Affymetrix SNP 6.0 and Illumina HT-12 v3 platforms respectively.  In addition, TP53 mutational profiling was 
performed.  Detailed description of the experimental assays and analytical methods used were described 
previously (Silwal-Pandit et al, 2015). In this cohort, patients with ER+ and/or lymph node negative tumours did 
not receive adjuvant chemotherapy, whilst those with ER- and/or lymph node positive tumours received adjuvant 
chemotherapy.  Breast Cancer Specific Survival (BCSS) is defined as the time (in months) from the date of 
primary surgery to the date of BC-related death.  
 
2.2 Gln-Pro enzymes protein expression 
Immunohistochemistry was conducted for PYCR1, ALDH18A1, and GLS using a large cohort of patients 
comprising a well-characterised consecutive series of early stage (TNM Stage I-III excluding T3 and T4 tumours) 
sporadic primary operable invasive BC. Patients (age ≤70 years) were enrolled into the Nottingham Tenovus 
Primary Breast Carcinoma Series, presented at Nottingham City Hospital between 1989 and 1998 (n=1,837) and 
managed in accordance to uniform protocol. Patients’ clinical history, tumour characteristics, information on 
therapy and outcomes are prospectively maintained. Outcome data was collected on a prospective basis.  
Primary antibody specificity (ALDH18A1 1:250 (HPA012604, Sigma-Aldrich, UK), GLS 1:1000 (EP7212, 
AbCam, UK) PYCR1 1:250 (HPA047660, Sigma-Aldrich, UK) was validated by western blotting (WB) using 
MCF7, MDA-MB-231 and SKBR3 human BC cell lines (American Type Culture Collection; Rockville, MD, 
USA). Proteins were detected using IRDye 800CW and 680RD fluorescent secondary antibodies (1:15000 
dilution. 926-32213 and 926-68072, LI-COR Biosciences) and visualised using the Odyssey Fc with Image 
Studio 4.0 (LI-COR Biosciences). Anti-β-actin primary antibody (Sigma-Aldrich) was used as a loading control 
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(1:5000). Specific bands were observed at the correct molecular weights for ALDH18A1 (87kDa), GLS (73kDa, 
65kDa) and PYCR1 (36kDa). An additional 55kDa band was observed for GLS and a 28kDa band for PYCR1 
which represent alternate isoforms of the proteins. 
 
2.3 Tissue arrays and Immunohistochemistry 
Tumour samples, 0.6mm cores, were arrayed as previously described (Abd El-Rehim et al, 2005). 
Immunohistochemical staining was performed on 4 μm thick sections using the Novolink polymer detection 
system (Leica Biosystems, RE7150-K), and following the manufacturer’s protocol. Primary antibodies for 
PYCR1, ALDH18A1, and GLS were diluted at 1:50 in Leica antibody diluent (RE7133). Negative (omission of 
primary antibody) and positive controls were included according to manufacturer’s data sheet. 
 
Stained TMA sections were scored using high resolution digital images (NanoZoomer; Hamamatsu Photonics, 
Welwyn Garden City, UK) at x20 magnification. Staining was assessed using the semi-quantitative, modified 
histochemical score (H-score) which evaluates both the intensity of staining and the percentage of stained cells 
resulting in a final score of 0-300 (Dang, 2012). For intensity, a score index of 0, 1, 2 and 3 corresponding to 
negative, weak, moderate and strong was used and the percentage of positive cells for each intensity was 
estimated subjectively. Dichotomisation of PYCR1, ALDH18A1, and GLS protein expression was determined 
using the median H-score. All cores were scored by NJ or HC and a pathologist (MA), blinded from the scores 
and the clinical data, scored 10% of cores for inter-observer concordance. There was high inter and intra-observer 
concordance between the scorers (Kappa score ≥0.6). 
Immunohistochemical staining and dichotomisation of other biomarkers included in this study were as per 
previous publications (Green et al, 2016). ER and PgR positivity was defined as ≥1% staining. Immunoreactivity 
of HER2 in TMA cores was scored using standard HercepTest guidelines (Dako). Chromogenic in situ 
Hybridisation (CISH) was used to quantify HER2 gene amplification in borderline cases using the HER2 FISH 
pharmDx™ plus HER2 CISH pharmDx™ kit (Dako) and was assessed according to the American Society of 
Clinical Oncology guidelines. BC molecular subtypes were defined based on the IHC profile as: Luminal A: 
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ER+/HER2- Low Proliferation (Ki67<10%), Luminal B: ER+/HER2- High Proliferation (Ki67≥10%), HER2-
positive class: HER2+ regardless of ER status, Triple Negative: ER-, PgR- and HER2-. Basal phenotype was 
defined as those tumours expressing cytokeratin (Ck) 5/6, and/or Ck14 and/or Ck17.  
 
2.4 Cluster analysis 
The partitioning around medoids (PAM) algorithm (also known as k-medoids algorithm) was used to cluster 
tumours based on gene and protein expression of the Gln-Pro enzymes as previously described (Soria et al, 2010). 
A number of cluster validity indices were used to determine the best number of clusters as the explicit input 
parameter to the PAM algorithm (Soria et al, 2010). 
 
2.5 Statistical analysis 
Statistical analysis was performed using SPSS 21.0 statistical software (SPSS Inc., Chicago, IL, USA). Univariate 
and multivariate analyses were performed by chi-squared test, Log rank and Cox regression analysis, respectively. 
One way ANOVA (Tukey) and Spearman’s Correlation coefficient were used for continuous data. Survival 
curves were analysed by Kaplan-Meier (Kaplan and Meier, 1958). A p-value <0.05 was considered significant. 
This study complied with reporting recommendations for tumour marker prognostic studies (REMARK) criteria 
(McShane et al, 2005). 
 
2.6 Ethics 
This study was approved by the Nottingham Research Ethics Committee 2 under the title ‘Development of a 
molecular genetic classification of breast cancer’. All samples from Nottingham used in this study were pseudo-
anonymised and collected prior to 2006 and therefore under the Human Tissue Act informed patient consent was 
not needed. Release of data was also pseudo-anonymised as per Human Tissue Act regulations. 
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3. Results 
 
3.1 Gln-Pro regulatory axis expression in breast cancer 
Gain of PYCR1 copy number primarily occurred in Luminal B tumours with 116/257 (45%) of all gains occurring 
(Table 1, p<0.001). Expression of PYCR1 mRNA was significantly higher in Luminal B tumours compared with 
Luminal A tumours, and high expression was also observed with HER2+ and Basal/TNBC subtypes (Figure 2a, 
p<0.001). However there was no association observed between PYCR1 protein expression and molecular classes 
(Figure 2b, p=0.118). 
Within the molecular classes, high ALDH18A1 mRNA was associated with HER2+ tumours although there was 
no difference observed with mRNA levels between Luminal A and Luminal B tumours (Figure 2c, p<0.001). 
Copy number gain of ALDH18A1 was associated with Basal tumours (Table 1, p<0.001). In contrast, high 
ALDH18A1 protein expression was seen in the ER+/HER2- High proliferation class compared with ER+/HER2- 
Low proliferation tumours (p=0.030) however significance was  not observed with all molecular classes (Figure 
2d; p=0.079).  
High copy number gain of GLS (Table 1), GLS mRNA (Figure 2e) and protein (Figure 2f) were all significantly 
associated with Basal/TNBC subtypes (p<0.001).  Lower GLS mRNA expression was seen in Luminal B tumours 
compared with Luminal A and the other molecular subtypes (Figure 2e; p<0.001). In contrast higher protein 
expression of GLS was seen in ER+/HER2- High proliferation compared with those classified as ER+/HER2- 
Low proliferation (Figure 2f; p=0.022), where highest expression was seen in the TNBC tumours (p<0.001).  
3.2 Gln-Pro regulatory axis confers poor prognosis in Luminal B breast cancer 
Breast tumours were further clustered based on the comparison of several indices comparing the gene expression 
of the Gln-Pro enzymes. These were characterised as follows: Cluster 1 (GLS-/ALDH18A1+/PYCR1+), Cluster 2 
(GLS+/ALDH18A1+/PYCR1+) and Cluster 3 (GLS+/ALDH18A1-/PYCR1-) (Figure 3a). The clusters were 
significantly associated with molecular subtypes of breast cancer where Cluster 1 were predominately Luminal B 
9 
and HER2+ tumours, Cluster 2 were associated with Basal/HER2+ tumours and Cluster 3 were primarily Luminal 
A and Normal subtypes (Table 2). With respect to patient outcome,  Cluster 1 tumours had the worst survival 
compared with Cluster 2 which had moderate outcome and Cluster 3 which showed the best survival (Figure 3b; 
p<0.001). In Cox Regression, Gln-Pro PAM Clusters remained independent of the standard clinicopathological 
parameters in predicting patient survival (Table 3; p=0.012).  
We looked to replicate the clusters derived from the mRNA expression using the protein expression of the Gln-
Pro enyzmes (using the median H-scores) which similarly showed that Cluster 1 (GLS-/ALDH18A1+/PYCR1+) was 
strongly associated with ER+/HER2- High Proliferation tumours, whereas Cluster 2 (GLS+/ALDH18A1+/PYCR1+) 
and Cluster 3 (GLS+/ALDH18A1-/PYCR1-) were associated with ER+/HER2- Low Proliferation and 
TNBC/HER2+ tumours respectively (Table 2; p=0.001). In terms of patient outcome, Cluster 1 tumours showed 
the worst survival compared with Clusters 2 and 3 (Figure 3c; p=0.0003). In Cox Regression analysis, the Glu-Pro 
Clusters remained independent of tumour grade, lymph node stage, tumour size, ER and HER2 status (Table 3; 
p=0.001). 
 
3.5 c-MYC is associated with high Gln-Pro enzymes in Luminal B tumours  
MYC mRNA was negatively correlated with PCYR1 (p=0.01) and ALDH18A1 (p<0.001) in all breast tumours, but 
not GLS (Table 4). In specific subtypes, MYC was positively correlated with PYCR1 mRNA in Luminal B 
tumours (p=0.006) and negatively correlated in Luminal A tumours (Table 4; p<0.001). The only other 
correlations between MYC and the Gln-Pro genes was a negative correlation with ALDH18A1 (p<0.001) in 
Luminal A (p<0.001) and HER2+ tumours (p=0.002).  
In terms of protein expression, MYC protein was positively associated with the individual protein expression of  
GLS and ALDH18A1 in all breast cancers, but was only associated with all three Gln-Pro enzymes in 
ER+/HER2- High Proliferation tumours (p<0.001, Table 4).   
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4. Discussion 
ER+/luminal tumours, which comprise the majority of BC (55-80%), remain a heterogeneous group in terms of 
molecular biology and patients’ outcome. Despite the significant benefit of hormone therapy, a proportion of 
patients with luminal BC develop recurrences and die of their disease. There is therefore a clear need for 
improved understanding of the biology of the luminal class of BC, with subsequent translation into more effective 
methods of prognostic and predictive stratification of this most common form of BC.  
 
Metabolic reprogramming in cancer including BC provides a vital role in the provision of supplementary elements 
including nutrients and energy which are essential for cellular growth. Tumour cells can become reliant on 
glutamine metabolism and become “addicted” to this amino acid for sustained proliferation/survival. 
Additionally, proline is often used as a precursor for other amino acids; therefore it is important in the synthesis of 
new proteins, as well as mediating redox signaling and protecting cells from oxidative stress (Kuo et al, 2016; 
Phang et al, 2015).  
 
It has also been shown that there is a major metabolic shift towards de novo proline synthesis in metastatic breast 
tumours (Richardson et al, 2008). High levels of MYC are required to maintain this glutaminolytic phenotype 
which not only sees an increase in Gln cellular uptake but also regulates Gln-Pro enzymes (Gao et al, 2009; Wise 
et al, 2008). MYC promotes the conversion of Gln to Pro by nearly tenfold by upregulating ALDH18A1 (Hu et 
al, 2008; Liu et al, 2012).  
 
Evidence of glutamine dependence in TNBC has previously been established (Cao et al, 2014; Gross et al, 2014; 
Hanahan & Weinberg, 2011; Lukey et al, 2016) but studies that address the prognostic significance of the key 
Gln-Pro enzymes in BC and their potential influence on Gln metabolism in the other molecular subtypes remains 
limited particularly in luminal BC. We have therefore investigated the expression of PYCR1, ALDH18A1 and 
GLS at the genomic, transcriptomic and proteomic level, and the impact of MYC on their expression, utilising a 
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large number of breast tumours in order to better understand the potential role of this regulatory axis in BC and its 
molecular subtypes, particularly in the luminal tumours.  
 
Overexpression of ALDH18A1 increases proline levels and lowers reactive oxygen species, as well as increasing 
cell survival. The increase in proline has been linked to protect cells against hydrogen peroxide induced cell 
death, as well as carcinogenic stressors; therefore promoting tumour growth and proliferation (Krishnan et al, 
2008). In line with this, we show that high ALDH18A1 confers a poor prognosis in Luminal B tumours. 
Inhibition of ALDH18A1 in melanoma significantly disrupts proline synthesis limiting cellular metabolism and 
decreasing cell viability, tumour growth and protein synthesis (Kardos et al, 2015; Liu et al, 2012). Knockdown 
or inhibition of ALDH18A1 in luminal B tumours could therefore potentially lead to a benefit in therapeutic 
targeting of this enzyme.  
 
PYCR1 is frequently overexpressed in many cancer types (Kuo et al, 2016); in particular breast, pancreatic and 
ovarian cancer (Natarajan et al, 2012; Phang et al, 2015). In meta-analysis, PYCR1 mRNA is highly expressed in 
the more aggressive BC subtypes, in addition to its protein in a small number of BC cases (Ding et al, 2017). 
Whilst we show similar results for mRNA in the METABRIC dataset, we were unable to confirm the translation 
into similarly high protein expression in TNBC and HER2+ BC nor its association with patient outcome. 
However, we do show that Luminal B have a high copy number gain of PYCR1 and consequently supports a role 
in this poor prognostic group of tumours. In prostate cancer, knockdown of PYCR1 results in the inhibition of cell 
proliferation via cell cycle arrest and enhanced apoptosis (Zeng et al, 2017) although the effect on breast cancer 
cells, particularly luminal B tumours remains to be determined. 
 
Levels and activity of GLS are significantly increased in TNBC and HER2+ breast cancer cell lines due to their 
propensity for glutamine dependence (Gross et al, 2014; Lukey et al, 2016; Wang et al, 2010) which we here 
confirm in vivo. However, we further demonstrate that GLS predicts a better outcome in HER2+ tumours and 
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selective GLS inhibitors, such as CB-839 which blocks glutamine consumption and reduces subsequent 
glutamate-derived metabolic intermediates, is likely to have limited use in these patients (Gross et al, 2014).  
 
Protein analysis also revealed that PYCR1 and ALDH18A1 are significantly associated with the MYC oncogene. 
This coincides with a plethora of studies which have shown that the MYC oncogene reprograms cell metabolism 
and causes an upregulation of genes involved in cancer (Li & Simon, 2013; Liu et al, 2012; Phang et al, 2013). 
Multiple studies have also supported the findings in this study, as the MYC oncogene has resulted in an increased 
expression of PYCR1 and ALDH18A1 to drive proline production; alongside fuelling the glutamine and MYC 
addiction that cancer cells exhibit (Li & Simon, 2013; Phang et al, 2015; Wise et al, 2008). 
 
It is thought that the MYC gene interacts with these enzymes by amplifying the existing transcriptional signalling 
of the gene leading to an increase in mRNA. MYC then drives the translation of mRNA in order to increase 
protein levels of the enzymes (Li & Simon, 2013; Natarajan et al, 2012). Interestingly, studies by Wei Liu et al 
have shown that downregulating the MYC oncogene with siRNAs not only reduced the conversion of glutamine 
to proline but also resulted in reduced mRNA and protein expression of ALDH18A1 and PYCR1 (Liu et al, 2015; 
Liu et al, 2012). Silencing MYC results in a reduction of cell proliferation and induction of apoptosis; as well as 
decreasing levels of PYCR1 and ALDH18A1 directly (Dang, 2012; Liu et al, 2012) and targeting all three 
enzymes led to the substantial reduction in proline production (Liu et al, 2012).  
Our observational findings of the Gln-Pro enzymes and their differing associations with MYC within the sub-
groups of breast cancer further support the many functions of MYC within glutaminolysis. We have previously 
shown that MYC is potentially driving glucose metabolism in ER-negative tumours and translational function in 
ER-positive tumours (Green et al, 2016), and we  further show in this study that MYC is likely driving the 
conversion of Gln to Pro within Luminal B tumours. Proline metabolism has a functional role in redox regulation 
and the conversion of Gln to Pro could be one mechanism where this balance can be achieved, especially in the 
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highly proliferative Luminal B tumours which show increased metabolic rates resulting in the accumulation of 
ROS (Benassi et al, 2006). 
 
In this study, we have shown that the Gln-Pro enzymes are highly expressed in a subset of ER+ tumours that have 
high proliferation, i.e. Luminal B tumours, and are related with poor patient outcome in this group, suggesting 
that expression of these enzymes are regulated and driven by alternative mechanisms within the different 
molecular subtypes of breast cancer and hence the pathways utilised for cell metabolism will also differ It was 
also interesting to observe the difference in gene and protein expression of these enzymes within the ER+/HER2- 
low proliferation tumours and TNBC/HER2+ tumours. This could have arisen due to the definitions used between 
mRNA (PAM50) and protein (ER plus Ki67 expression). It might also reflect the differences in transcription and 
translational modifications. 
 
The high expression of the Gln-Pro regulatory axis in Luminal B tumours is perhaps not unsurprising as they will 
have heavier demands of nutrients and energy essential for cell survival and proliferation compared with Luminal 
A tumours and it is known that tumours will alter their metabolic profiles to meet the needs for their growth and 
proliferation. This is supported by a study carried out by Kim et al in which differential expression patterns of 
glutamine metabolism-related proteins were identified according to the molecular subtype of breast cancer, with 
HER2+ tumours displaying highest glutamine metabolic activity and higher MYC amplification and Luminal B 
tumours displaying higher glutamine metabolic activity than Luminal A tumours (Kim et al, 2013). 
We further show that within the highly proliferative luminal B tumours, high expression of the Gln-Pro enzymes 
are all significantly associated with MYC suggesting that it is the driving force behind the metabolic status for 
this subclass of breast cancer. 
Therefore, we believe that continued refinement in understanding of the biological diversity of BC, particularly 
the Luminal B class, with linked development of classification strategies suitable for routine clinical use are 
essential to achieve a personalised approach to BC management. Further investigation of Gln metabolism using a 
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variety of in vitro functional assays are therefore essential to assess its the potential therapeutic value in the highly 
proliferative aggressive subclass of ER+ Luminal B BC. 
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Titles and Legends to Figures 
Figure 1. Schmatic representation of the enzymes involved in the glutamine regulatory axis 
Figure 2. Gln-Pro enzyme mRNA expression in breast cancer molecular subtypes 
Figure 3. Gln-Pro clusters in breast cancer. Boxplots for a) mRNA b) protein. Patient outcome c) mRNA d) 
protein 
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